Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Biotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...

Laura is an editor and staff writer at IFLScience. She obtained her Master's in Experimental Neuroscience from Imperial College London.

InDevR partners with Aldevron to describe how the VaxArray 5′CapQ assay can be used to measure intact mRNA in a single assay to streamline bioprocess development.

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism (35% comfortable with technology) and challenges translating ...

A similar challenge arises at the microscopic level when lipid nanoparticles (LNPs)—the revolutionary drug delivery vehicles behind the COVID-19 vaccines—attempt to deliver mRNA to cells.

We did not, however, imagine that over the intervening months, vaccination in general, and mRNA vaccines in particular, would escalate into a political wedge issue that threatens to undermine the ...

The mRNA-based SARS-CoV-2 vaccines are believed to impart protection ... Avidity ELISAs were performed on sample dilutions with optical densities (OD) between 0.50 to 1.30 OD units at 450nM; 1.00 was ...

mRNA is naturally occurring in every cell of the body and is involved in protein synthesis. Cohn said pieces of the legislation might make sense — for example, it would block anyone who’s received ...